Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator

Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation

(2016) Kristine Færch et al.   DIABETES

Molecular targeting of the GK-GKRP pathway in diabetes

(2014) Clarence Hale et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells

(2014) Y. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Relationship of Glucokinase Activator–induced Hypoglycemia with Arteriopathy, Neuronal Necrosis, and Peripheral Neuropathy in Nonclinical Studies

(2014) John C. Pettersen et al.   TOXICOLOGIC PATHOLOGY

Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin

(2013) J. P. H. Wilding et al.   DIABETES OBESITY & METABOLISM

Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice

(2013) Nirav Dhanesha et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes

(2013) Jeffrey A Pfefferkorn   Expert Opinion on Drug Discovery

Evolution of glucose utilization: Glucokinase and glucokinase regulator protein

(2013) David M. Irwin et al.   MOLECULAR PHYLOGENETICS AND EVOLUTION

Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors

(2013) David J. Lloyd et al.   NATURE

Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans

(2012) Frédéric De Ceuninck et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

(2011) G. E. Meininger et al.   DIABETES CARE

Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice

(2011) Maria Sörhede Winzell et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Discovery of (S)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus

(2011) Jeffrey A. Pfefferkorn et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs

(2011) J.-i. Eiki et al.   MOLECULAR PHARMACOLOGY

Genetics of type 2 diabetes

(2010) Galina Smushkin et al.   CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE

The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver

(2009) Nicola L. Beer et al.   HUMAN MOLECULAR GENETICS

Investigation of Functionally Liver Selective Glucokinase Activators for the Treatment of Type 2 Diabetes

(2009) Gregory R. Bebernitz et al.   JOURNAL OF MEDICINAL CHEMISTRY

Assessing the potential of glucokinase activators in diabetes therapy

(2009) Franz M. Matschinsky   NATURE REVIEWS DRUG DISCOVERY

Glucokinase and molecular aspects of liver glycogen metabolism

(2008) Loranne Agius   BIOCHEMICAL JOURNAL

Molecular Physiology of Mammalian Glucokinase

(2008) P. B. Iynedjian   CELLULAR AND MOLECULAR LIFE SCIENCES

Interaction Effect of Genetic Polymorphisms in Glucokinase (GCK) and Glucokinase Regulatory Protein (GCKR) on Metabolic Traits in Healthy Chinese Adults and Adolescents

(2008) C. H.T. Tam et al.   DIABETES

Targeting Hepatic Glucokinase in Type 2 Diabetes: Weighing the Benefits and Risks

(2008) L. Agius   DIABETES

The Common P446L Polymorphism in GCKR Inversely Modulates Fasting Glucose and Triglyceride Levels and Reduces Type 2 Diabetes Risk in the DESIR Prospective General French Population

(2008) M. Vaxillaire et al.   DIABETES

Common Missense Variant in the Glucokinase Regulatory Protein Gene Is Associated With Increased Plasma Triglyceride and C-Reactive Protein but Lower Fasting Glucose Concentrations

(2008) M. Orho-Melander et al.   DIABETES

Glucokinase activators in diabetes management

(2008) Matthew Coghlan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Biophysical Characterization of the Interaction between Hepatic Glucokinase and Its Regulatory Protein

(2008) Oliver Anderka et al.   JOURNAL OF BIOLOGICAL CHEMISTRY